[go: up one dir, main page]

AR118273A2 - Excipiente estabilizante para una vacuna de virus completo inactivado - Google Patents

Excipiente estabilizante para una vacuna de virus completo inactivado

Info

Publication number
AR118273A2
AR118273A2 ARP200100627A ARP200100627A AR118273A2 AR 118273 A2 AR118273 A2 AR 118273A2 AR P200100627 A ARP200100627 A AR P200100627A AR P200100627 A ARP200100627 A AR P200100627A AR 118273 A2 AR118273 A2 AR 118273A2
Authority
AR
Argentina
Prior art keywords
stabilizing excipient
virus vaccine
complete virus
inactivated complete
inactivated
Prior art date
Application number
ARP200100627A
Other languages
English (en)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR118273A2 publication Critical patent/AR118273A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a una composición de vacuna que comprende: a) virus entero inactivado, y b) un excipiente estabilizante que comprende: i) una solución amortiguadora, ii) un mezcla de aminoácidos esenciales y no esenciales, iii) un disacárido, iv) un poliol, v) un agente quelante, vi) urea o un derivado de la urea, y vii) un tensioactivo no iónico.
ARP200100627A 2009-10-07 2020-03-06 Excipiente estabilizante para una vacuna de virus completo inactivado AR118273A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0904795 2009-10-07

Publications (1)

Publication Number Publication Date
AR118273A2 true AR118273A2 (es) 2021-09-22

Family

ID=42123015

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103658 AR078558A1 (es) 2009-10-07 2010-10-07 Excipiente estabilizante para una vacuna de virus completo inactivado
ARP200100627A AR118273A2 (es) 2009-10-07 2020-03-06 Excipiente estabilizante para una vacuna de virus completo inactivado

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP100103658 AR078558A1 (es) 2009-10-07 2010-10-07 Excipiente estabilizante para una vacuna de virus completo inactivado

Country Status (16)

Country Link
US (2) US8557253B2 (es)
EP (2) EP3915586A1 (es)
CN (1) CN102281900B (es)
AR (2) AR078558A1 (es)
AU (1) AU2010304898B2 (es)
BR (1) BR112012008000B1 (es)
ES (1) ES2862910T3 (es)
MA (1) MA33723B1 (es)
MX (1) MX338300B (es)
PE (1) PE20121405A1 (es)
PH (1) PH12012500550A1 (es)
PL (1) PL2485766T3 (es)
PT (1) PT2485766T (es)
RU (1) RU2560675C2 (es)
WO (1) WO2011042663A1 (es)
ZA (1) ZA201202758B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
BR112013005049A2 (pt) * 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
KR20140033171A (ko) * 2011-05-26 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 비활성화된 뎅기 바이러스 백신
EP3744833A1 (en) 2011-06-28 2020-12-02 Leukocare Ag Stabilisation method for viruses
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
WO2015034924A1 (en) * 2013-09-03 2015-03-12 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
EP3060247A1 (en) 2013-10-25 2016-08-31 Leukocare Ag A novel method for the production of stabile vaccines
AR099470A1 (es) * 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN104548085B (zh) * 2014-12-09 2018-01-19 吕宏亮 一种口蹄疫全病毒颗粒疫苗组合物及其制备方法和应用
CN106163554B (zh) 2014-12-23 2021-09-07 依生生物制药(新加坡)私人有限公司 一种包含pika佐剂的狂犬病组合物
CN105816879A (zh) * 2016-03-17 2016-08-03 广州市嘉合生物技术有限公司 用于提高冻干病毒疫苗在常温下保存的效力的冻干稳定剂
EP3512496B1 (en) 2016-09-16 2025-07-30 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
US11166915B2 (en) 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
WO2018050874A1 (en) * 2016-09-16 2018-03-22 Leukocare Ag A novel method of producing a liquid biopharmaceutical drug product
GB201815011D0 (en) * 2018-09-14 2018-10-31 Adaptimmune Ltd Viral assay method
WO2020113197A1 (en) * 2018-11-30 2020-06-04 Vaccine Stabilization Institute Viral formulations containing amino acids
EP4054627A4 (en) * 2019-11-07 2023-12-06 Cornell University Use of membrane inhibitors to enhance vaccine development against enveloped viruses
CN112245394B (zh) * 2020-10-21 2022-10-11 成都柏奥特克生物科技股份有限公司 一种疫苗保护剂
WO2023023371A1 (en) * 2021-08-20 2023-02-23 Vaccine Stabilization Institute Formulations containing amino acids for stabilizing lipid enveloped viral and non-viral vectors
CN114377127B (zh) * 2022-01-25 2023-10-24 天津市中升挑战生物科技有限公司 一种三联卵黄抗体制剂及其制备方法和应用
CN117003897B (zh) * 2023-08-10 2024-10-29 深圳泰华赛尔生物科技有限公司 靶向Claudin18.2的CAR-T细胞及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR952310A (fr) 1946-09-20 1949-11-15 Ford Transmission par accouplement hydraulique jumelé
JPS577423B2 (es) 1972-12-29 1982-02-10
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5565209A (en) * 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
FR2633518B1 (fr) * 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
FR2801900B1 (fr) 1999-12-03 2004-02-27 Pasteur Merieux Serums Vacc Methode de production de cellules animales adherentes
CA2557800A1 (en) 2004-03-22 2005-10-06 Yossef Raviv Cellular and viral inactivation
CN101095950B (zh) * 2006-06-30 2011-01-26 辽宁成大生物股份有限公司 一种稳定的人用狂犬病疫苗冻干制剂及其制备
GB0615312D0 (en) * 2006-08-02 2006-09-13 Univ Dundee Protein Solubilisation
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
FR2944292B1 (fr) * 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine

Also Published As

Publication number Publication date
US20110081380A1 (en) 2011-04-07
AR078558A1 (es) 2011-11-16
ES2862910T3 (es) 2021-10-08
RU2560675C2 (ru) 2015-08-20
ZA201202758B (en) 2013-06-26
AU2010304898A1 (en) 2012-05-17
CN102281900A (zh) 2011-12-14
PT2485766T (pt) 2021-03-18
US20140037684A1 (en) 2014-02-06
BR112012008000B1 (pt) 2021-07-13
MA33723B1 (fr) 2012-11-01
PE20121405A1 (es) 2012-11-02
EP2485766A1 (fr) 2012-08-15
US9028839B2 (en) 2015-05-12
EP3915586A1 (fr) 2021-12-01
MX2012003935A (es) 2012-05-08
MX338300B (es) 2016-04-11
BR112012008000A2 (pt) 2016-03-29
CN102281900B (zh) 2013-07-03
EP2485766B1 (fr) 2020-12-30
PL2485766T3 (pl) 2021-09-06
AU2010304898B2 (en) 2015-03-19
RU2012118386A (ru) 2013-11-20
PH12012500550A1 (en) 2015-05-08
US8557253B2 (en) 2013-10-15
WO2011042663A1 (fr) 2011-04-14

Similar Documents

Publication Publication Date Title
AR118273A2 (es) Excipiente estabilizante para una vacuna de virus completo inactivado
CL2011003113A1 (es) Composicion adyuvante acuosa que comprende un agonista de tlr-4 y una saponina y un agente de isotonicidad no ionico; proceso para la preparacion de una composicion inmunogenica.
CL2011002460A1 (es) Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.
CL2011002082A1 (es) Composicion farmaceutica que comprende un inhibidor de nucleosido polimerasa y un inhibidor de proteasa macrociclica; proceso para preparar dicha composicion farmaceutica; metodo para tratar o mejorar una infeccion con virus de la hepatitis c, fibrosis hepatica y alteracion de la funcion hepatica.
AR088524A1 (es) Composicion descongelante, proceso de preparacion, conjunto de parte y uso
MX2012009180A (es) Variantes y composiciones que comprenden variantes con alta estabilidad en presencia de un agente quelante.
BR112012029517A2 (pt) formulações de fragrância, métodos de fabricação e artigos compreendendo as mesmas.
AR086871A1 (es) Composicion descongelante, proceso de preparacion, conjunto de partes y uso
BR112013026935A2 (pt) preparação de base aquosa, composição para limpeza de superfícies de materiais refratários e uso da composição
AR086872A1 (es) Composicion descongelante, proceso de preparacion, conjunto de partes y uso
MX349119B (es) Vacuna de virus de dengue inactivado.
AR080111A1 (es) Metodos y composiciones de inmunizacion
WO2012093406A3 (en) A combination heptavalent vaccine
CL2011000262A1 (es) Virus de bronquitis infecciosa (bi) derivado de un virus similar a qx-bi; composicion de vacuna que comprende dicho virus; procedimiento para preparar dicho virus.
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
GT201200259A (es) Hidrato del hidrocloruro de agomelatina y preparación de éste
GB2539148A (en) Vaccine compositions
NZ611531A (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
BR112015012453A2 (pt) método e composição para sincronizar o tempo de inseminação em leitoas
WO2013104995A3 (en) Compositions and methods for treating viral infections
BR112014007099A2 (pt) formulação corante aquosa, método para tingir um artigo de meta-aramida e artigo de meta-aramida
ECSP12012156A (es) Hidrato del hidrobromuro de agomelatina y
MX359103B (es) Composiciones y sus usos en el tratamiento de infecciones virales.
PH12015502115A1 (en) Compositions and methods for live, attenuated alphavirus formulations
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.

Legal Events

Date Code Title Description
FC Refusal
FC Refusal